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Summary
The VKORC1 Asp36Tyr single nucleotide polymorphism (SNP) is one of the most promising
predictors of high warfarin dose, but data on its population prevalence is incomplete. We
determined the frequency of this SNP in participants from seven countries on four continents and
investigated its effect on warfarin dose requirement. 1000 samples were analyzed to define the
population prevalence of this SNP. Those samples included individuals from Egypt, Ghana,
Sudan, Kenya, Saudi Arabia, Peru and African Americans from the United States. 206 Egyptian
samples were then used to investigate the effect of this SNP on warfarin dose requirements. This
SNP was most frequent among Kenyans and Sudanese, with a minor allele frequency (MAF) of
6% followed by Saudi Arabians and Egyptians with a MAF of 3% and 2.5%, respectively. It was
not detected in West Africans, based on our data from Ghana, and a large cohort of African
Americans. Egyptian carriers of the VKORC1 Tyr36 showed higher warfarin dose requirement
(57.1±29.4 mg/week) than those with the Asp36Asp genotype (35.8±16.6 mg/week; P<0.03). In
linear regression analysis, this SNP had the greatest effect size among the genetic factors (16.6
mg/week increase in dose per allele), and improved the warfarin dose variability explained in
Egyptians (model R2 from 31% to 36.5%). The warfarin resistant VKORC1 Asp36Tyr appears to
be confined to north-eastern Africa and nearby Middle-Eastern populations, but in those
populations where it is present, it has a significant influence on warfarin dose requirement and the
percent of warfarin dose variability that can be explained.
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Warfarin was first approved for clinical use in 1954, and since then, it has been the mainstay
oral anticoagulant therapy for treatment and prevention of thromboembolic events.
However, its narrow therapeutic index and wide inter-patient variability in dose
requirements for a therapeutic warfarin effect make it an extremely challenging
pharmacological agent to utilize clinically (1-3).
Numerous pharmacogenetic studies have been conducted with warfarin, and have shown
that warfarin dose requirements, risk of bleeding and time to reach a stable warfarin dose are
influenced by demographic factors (age, gender and ethnicity), clinical factors (smoking,
concurrent medications, illness and diet) and genetic variables (4-7). In 2007, and again in
2010, the Food and Drug administration (FDA) updated the warfarin label with information
on warfarin pharmacogenetics. The 2010 update included a dosing guidance based on
genetic factors, specifically CYP2C9 and VKORC1 polymorphisms, which are strongly
associated with warfarin dose requirements, with the variant alleles leading to lower
warfarin dose (1, 8-11). The inclusion of the CYP2C9 and VKORC1 warfarin sensitivity
polymorphisms with clinical factors explain more than 50% of the warfarin dose variability
in those of European ancestry, however, less variability was explained in other ethnic
populations (1, 9, 12, 13). Thus, it is important to identify other genetic or clinical factors
that may help improve the prediction of warfarin dose requirements in non-Europeans. It is
also clear that even in whites, there is a substantial portion of the variability yet to be
explained, and it is important to note that most of the genetic factors identified to date help
to explain requirements for a low dose of warfarin; the genetic underpinnings for high
warfarin dose requirements, or warfarin resistance, are poorly understood.
The one variant that has been most strongly associated with high warfarin dose requirements
is the VKORC1 coding Asp36Tyr (D36Y; rs61742245) variant. This variant appears to
exhibit large differences in population prevalence. For example, it is relatively common in
Ethiopians with minor allele frequency (MAF) of 15%, and Ashkenazi Jews (MAF 4%), less
common in Israeli Jews (MAF 1.5%) and Arab Muslims in Israel (MAF 1%), and has a
MAF of 0.5% in Sephardic, Yemenite, and North African Jews (10, 14-18). On the other
hand, it was absent in over 700 non-Jewish Caucasian controls, 180 Israelis of Druze
descent, 220 Han Chinese, 240 Southeast Indians and 213 South African individuals (17,
19-22).
The primary objective of this study was to better define the population frequencies of this
variant, through testing of populations in seven countries on four continents, including five
African and Middle Eastern countries, the United States (African Americans), and Peru. We




A total of 1000 samples were included in the analysis to define population prevalence.
Those samples included individuals from Egypt, Ghana, Sudan, Kenya, Saudi Arabia, Peru
and African Americans from the United States, as shown in Table 1. All participants
provided informed consent and the study protocol was approved by relevant local
Institutional Review Boards.
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207Egyptian patients were enrolled while taking chronic warfarin therapy (Marevan®;
GlaxoSmithKline, Cairo, Egypt) for various indications as previously described (23).
Eligible patients were those who were taking stable weekly doses of warfarin for three
consecutive clinic visits, occurring over a minimum time period of 2 months. A stable
weekly maintenance dose of warfarin was defined as a dose that did not vary by more than
10% between clinic visits. The international normalized ratio (INR) at each of the three
visits had to be in the patient’s specific goal INR range. Liver cirrhosis, advanced
malignancy, hospitalization within the earlier 4 weeks, and febrile/diarrheal illness within
the past 2 weeks were the exclusion criteria of this study. The Egyptian warfarin
pharmacogenetic study was approved by the Research Ethics Committee at the Faculty of
Medicine, Ain Shams University, Cairo, Egypt.
Genotyping procedure
VKORC1 Asp36Tyr polymorphism was genotyped at the University of Florida, University
of North Carolina and University of Illinois at Chicago. Genotyping was done using the
same protocol at all 3 sites including PCR followed by pyrosequencing as previously
described (24). The following forward: biotinylated-5′TCTACGCGCTGCACGTGA-3′;
and reverse PCR primers: 5′-AGAAGACGCGCGAACAGCT-3′ along with reverse
sequencing primer: 5′-AGCGCGCGGTAATCCC-3′ were used in this analysis.
The standard PCR reaction mixture used for the amplification of the target sequence
consisted of 12.75 ul including 6.5 ul of ABI PCR master mix with Taq DNA polymerase, 1
ul dimethylsulfoxide (Sigma-Aldrich, St Louis, Missouri, USA), 1 ul of each primer
(Invitrogen, Carlsbad, California), 1.25 ulof purified water, and 2 ul of genomic DNA. An
annealing temperature of 58°C was used for the PCR reaction.
Statistical analysis
The mean weekly warfarin dose in the Egyptian cohort was calculated by taking the average
of the warfarin dose for three consecutive clinic visits that was documented for each patient.
Categorical variables were represented as percentages. Numerical variables were
represented as mean ± standard deviation or median and interquartile range as appropriate.
Hardy-Weinberg equilibrium was assessed by allele counting and x2 analysis with one
degree of freedom, and Fisher’s exact test for populations with small sample size (e.g.
Kenyans) (25). . Median weekly warfarin dose differences by VKORC1 Asp36Tyr
genotypes were evaluated by nonparametric methods (Mann-Whitney U-test)
A stepwise linear regression model was used to assess the explanatory power of VKORC1
Asp36Tyr polymorphism in relation with mean weekly warfarin dose and whether this
polymorphism improved our previous explanatory model in Egyptians (23). This regression
analysis included our previous genetic variables [VKORC1 (rs9923231),
CYP2C9*2*3*4*5*8, CYP4F2 (rs2108622), APOE (rs429358 and rs7412), and CALU
(rs339097)] which were available for 195 patients only. Additionally, it included non-
genetic factors that may contribute to warfarin dose requirements. The VKORC1 Asp36Tyr
was coded: Asp/Tyr as 1 and Asp/Asp (wild type) as 0. Square root transformation of the
dose was applied to improve model fit and limit heteroscedascity. Statistical significance
was defined as p < 0.05. All statistical analyses were carried out with SPSS (version 17.0 for
windows; SPSS Inc., Chicago, Illinois, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC)
software.
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Complete genotyping data were available for 1000 samples. All genotypes were in Hardy-
Weinberg equilibrium. One Egyptian sample was removed from the analysis since it was not
successfully genotyped. Prevalence of the VKORC1 Asp36Tyr SNP in the populations
studied is shown in Table 1. These data reveal the presence of the VKORC1 Asp36Tyr SNP
in all East African countries studied, along with Saudi Arabia. However, this SNP was not
detected in the one West African country (Ghana), in African Americans (who derive
largely from West Africa) (26, 27) and in Peruvians. The prevalence of this SNP was highest
among Kenyans and Sudanese with a MAF of 6%, followed by Saudi Arabians and
Egyptians with a MAF of 3% and 2.5%, respectively. ▶Figure 1 displays a world map that
indicates the countries from which Asp36Tyr frequency data have been previously reported
with the new data from this study. Countries in which this SNP is prevalent are shown in
decreasing shades of gray, highlighting the greatest prevalence of this SNP in northeast
Africa and western parts of the Middle East, and its absence or being very rare in the other
studied populations.
Ten patients in the Egyptian warfarin pharmacogenetic study were carriers of the VKORC1
Asp36Tyr variant. Those carriers had a stable warfarin dose (57.1 ± 29.4 mg) significantly
higher than non-carriers (35.8 ± 16.6 mg/week, P = 0.03); as shown in ▶Fig. 2). The range
of the warfarin dose requirement among the VKORC1 Asp36Tyr carriers was 21 mg/week
to 98 mg/week. Among the 15 patients requiring ≥ 70 mg/week (10 mg/day) in this cohort,
five (33%) were VKORC1 Asp36Tyr carriers. Among the other five VKORC1 Asp36Tyr
carriers, four of them carried variants in VKORC1 (−1639 G>A, rs9923231) or other genes
that associate with lower dose requirements, as shown in Table 2.
We previously published a multivariate regression analysis of factors significantly
influencing warfarin dose requirements in Egyptians, and showed genetic and clinical
variables that explained (model R2) 31% of the warfarin dose variability (23). The VKORC1
Asp36Tyr variant was significantly associated with warfarin dose variability when added to
the previous regression analysis, and increased the model R2 to 36.5%, Table 3).
Discussion
The VKORC1 Asp36Tyr (rs61742245) SNP was first described as a warfarin resistance
SNP in 2007 (14, 28), but its frequency has previously been reported in limited numbers of
populations. We provide substantial additional data on population prevalence in this study,
and our data, combined with the existing literature provides strong evidence for the
restriction of this genetic variant to northeastern Africa and neighboring Middle-Eastern
regions. However, we did not detect any variant carriers among those tested from Ghana or
our large cohort of African Americans, who derive largely from West Africa, suggesting this
allele is absent or very rare among west Africans.
In our previous Egyptian warfarin pharmacogenetic study, we reported significant
association with warfarin sensitivity markers in the VKORC1, CYP2C9 and APOE but did
not investigate genetic markers explaining warfarin resistance. The current study is
consistent with the previous literature on VKORC1 Asp36Tyr (14-16, 29, 30), and showed
that Egyptian carriers of the VKORC1 Asp36Tyr variant require higher warfarin doses than
wild type carriers (P = 0.03). The inclusion of this variant in our previous regression analysis
improved the percent of variability explained by an absolute 5.5% when compared to our
previous model. Moreover, this variant had the largest effect size among the significantly
associated genetic variants in our linear regression model, resulting in a 16.6 mg/week
higher warfarin dose per allele.
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A total of 10 patients were identified as carriers of VKORC1 Asp36Tyr polymorphism, five
of those patients required a mean warfarin dose of 83.3 ± 10.6 mg/week, while the other 5
carriers required a mean warfarin dose of 31 ± 10.6 mg/week. The lower dose requirements
in this latter group is likely explained in part by the fact that four of the five had variants in
VKORC1 (−1639G>A, rs9923231) or other genes that associate with lower warfarin dose
requirements. This lower dose might also be explained by other warfarin sensitive genetic
variants or environmental factors like diet that were not investigated in our study.
It is of interest to note that only 33% of warfarin resistance cases (dose requirements ≥ 10
mg/day) carried this variant allele, meaning there is a large portion of patients within this
high dose group for which the insensitivity to warfarin remains unexplained. This is
consistent with a recent study by Watzka et al., who screened for VKORC1 mutations in 626
individuals with marked warfarin resistance. They found only six (or < 1%) of these patients
carrying the Asp36Tyr variant, three from Russia, one from Turkey and an African
American (30). Moreover, a recent study by Kurnik et al., who studied the effect of the
VKORC1 Asp36Tyr polymorphism on warfarin maintenance dose in 210 Israelis,
consistently showed that only 31% of patients taking a warfarin dose ≥ 10 mg/day carried
this variant allele (31). They also showed that the presence of a single allele of this variant
more than doubled the maintenance warfarin dose, and by adding this variant to the
International Warfarin Pharmacogenetic Consortium (IWPC) dose prediction model, a
significantly better performance in the warfarin dose prediction was detected (R2 from 27%
to 47.2%)(31). The data from the current study, from Watzka, et al. (30) and Kurnik et al.
(31) studies suggest that in those populations where VKORC1 Asp36Tyr is prevalent, it
explains a portion of warfarin resistance, yet in all population groups, including those where
VKORC1 Asp36Tyr is prevalent, substantial additional work is needed to better understand
the genetic underpinnings of warfarin insensitivity.
In conclusion, this study provides greater insight into the population prevalence of the
VKORC1 Asp36Tyr, and suggests that it occurs primarily in northeastern African and
Middle-Eastern populations. Our data on warfarin dose requirements in Egyptian carriers of
the variant allele further support the importance of the variant in leading to insensitivity to
warfarin therapy. The improvement in the prediction of warfarin dose variability suggests
that the inclusion of this SNP in dosing algorithms in those populations where the SNP is
prevalent, particularly for those in northeastern Africa and the Middle-East, may lead to
improved warfarin dose prediction. However, this polymorphism appears to be unimportant
to West Africans, African Americans and Peruvians, along with other populations where it
has not been detected (e.g. Europeans and Asians) (19, 20). Further research is required to
explain the genetic or other causes of warfarin resistance.
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Figure 1. World map showing VKORC1 Asp36Tyr geographical distribution
Populations having the variant were listed in a descending order according to the VKORC1
Asp36Tyr frequency in each studied population. Populations having the VKORC1
Asp36Tyr highest frequency were represented by dark gray color, followed by lighter gray
colors in populations with lower frequency. Cross hatches represent populations in which
this variant was not detected . The countries in bold italic represent the seven populations
included in our study; the remainder represent previously studied populations (14-16, 21, 22,
32, 33).★ Jewish and Israeli populations include: Ashkenazi Jews (4%), Israeli Jews (1.5%),
Arab Muslims in Israel (1%), Sephardic Jews (0.5%) and North African Jews (0.5%).
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Figure 2. Box plot showing the effect of VKORC1 Asp36Tyr polymorphism on warfarin dose
requirements in Egyptians
The box represents the values from the 25 to 75% percentile. The horizontal line represents
the median. The diamond represents the mean. The vertical line extends from the minimum
to the maximum value, excluding outlier and extreme values which are marked as closed
circles. Nonparametric test (Mann-Whitney U test) was used to compare the warfarin dose
requirements between the two groups, showing a significant difference of P = 0.03.
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Table 1
VKORC1 Asp36Tyr genotype prevalence in the 7 studied populations.
Asp36Tyr Genotypes Tyr36Allele
Frequency,
%Population Na Tyr/Tyr Asp/Tyr Asp/Asp
Kenya 41 1 3 37 6
Sudan 43 0 5 38 6
Saudi Arabia 85 0 5 80 3
Egypt 206 0 10 196 2.5
Ghana 85 0 0 85 <0.5b
Peru 71 0 0 71 <0.7b
African
American 469 0 0 469 <0.1b
a
Number of individuals genotyped from each population.
b
Tyr36allele frequency (< X %), where X is the frequency if there had been one heterozygous subject in a given population that we tested.
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Table 2
VKORC1 −1639G>A, and CYP2C9*2*3*4*5 and *8 genotypes distribution among the ten VKORC1











1 Asp/Tyr WT♣ WT 98
2 Asp/Tyr WT WT 87.5
3 Asp/Tyr G/A WT 84
4 Asp/Tyr WT WT 77
5 Asp/Tyr G/A WT 70
6 Asp/Tyr WT WT 45.5
7 Asp/Tyr G/A WT 38.5
8 Asp/Tyr G/A WT 24.5
9 Asp/Tyr G/A WT 24.5
10 Asp/Tyr G/A *3/*3 21
#
VKORC1 (−1639G>A, rs9923231), CYP2C9 tested for *2, *3, *4, *5, and *8 which were previously published (23).
♣
WT refers to a wild type genotype (G/G for VKORC1 and *1/*1 for CYP2C9).
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Table 3
Linear Regression stepwise modeling association between mean weekly warfarin dose (square root
transformed) as a dependent variable and genetic and non-genetic factors as independent variables.
Predictor Coefficient Standard Error PartialR2(%) Pvalue
Intercept 8.19 0.319
VKORC1# variant −0.62 0.131 11.5 <0.0001
Age (decades) −0.32 0.05 9.2 <0.0001
CYP2C9# variant −0.56 0.17 6.6 0.002
Pulmonary Embolism 1.21 0.54 2.6 0.026
APOE ε2 −0.59 0.21 2.7 0.006
VKORC1 Asp36Tyr§ 0.96 0.38 2.0 0.013
Smoking Status 0.58 0.25 1.9 0.021
Model R2 36.5 <0.0001
#
VKORC1 (−1639G>A; rs9923231), CYP2C9 *2, *3, *4, *5, and *8
§
None of the VKORC1 Tyr36 allele carriers had pulmonary embolism
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